Absci Corp SEC Filings

Absci Corp senior vice president and chief accounting officer Todd Bedrick reported routine equity compensation grants and related tax withholding. He received 49,600 shares of common stock as restricted stock units under the 2021 Stock Option and Incentive Plan, which will vest in three equal annual installments starting on March 1, 2027, contingent on continued service.

Bedrick was also granted stock options covering 195,900 shares of common stock at an exercise price of $2.80 per share, expiring on March 1, 2036, vesting in substantially equal annual installments over three years beginning March 1, 2027. In connection with the vesting of restricted stock units, 5,282 shares of common stock were withheld by Absci to cover tax obligations, leaving him with 216,942 common shares held directly; this withholding was not a discretionary market sale.

Absci Corp CEO Sean McClain reported equity compensation grants and related tax withholding. On 2026-03-02, he received 406,200 shares of Common Stock as a restricted stock unit award and a stock option for 1,603,200 shares of Common Stock at an exercise price of $2.80 per share, both vesting in three substantially equal annual installments starting on March 1, 2027, subject to continued service. On 2026-03-03, 25,316 shares of Common Stock were withheld by Absci to cover tax obligations from RSU vesting, which the filing notes was not a discretionary trade. After these transactions, McClain directly held 8,715,451 shares of Common Stock.

Absci Corp’s Chief Innovation Officer buys additional shares. Executive Andreas Busch reported an open-market purchase of 100,000 shares of Absci common stock at a price of $2.29 per share on March 12, 2026, in accordance with the company’s trading policies. This increased his direct ownership to 421,446 shares.

Absci Corporation updated its governance and leadership structure. The board approved amended and restated indemnification agreements for all current directors and officers, adding more detailed change-in-control definitions, a presumption of good faith for officer indemnitees, coverage for separate counsel after a change in control, and an exclusion for incentive- and equity-based compensation subject to Rule 10D-1 clawbacks.

Chief Innovation Officer Andreas Busch, Ph.D. will retire effective March 31, 2026, then serve as a scientific advisor for two years starting April 3, 2026. Under an Advisor Agreement, he will receive a $25,500 annual cash retainer and equity awards of stock options for 22,800 shares and 5,800 restricted stock units. The company extended the exercise period on 2,489,290 vested stock options he holds, generally until three months after his advisory service ends or their original expiration, with specific provisions for cause, death, or disability; all unvested options at retirement will lapse.

Absci also announced the appointment of Ransi Somaratne, M.D., a veteran clinical development leader, as Chief Medical Officer to lead clinical strategy for its AI-designed therapeutics pipeline, including the ABS-201 program.

Pangalos Menelas N reported acquisition or exercise transactions in this Form 4 filing.

Absci Corp director Menelas N. Pangalos reported equity awards tied to his role on the company’s scientific advisory board. He received stock options for 22,800 shares and a grant of 5,800 Restricted Stock Units (RSUs), both at no cash cost per share.

The RSUs are scheduled to vest and settle over one year beginning on January 1, 2026, in substantially equal monthly installments, conditioned on his continuous service. The stock options follow the same one-year, monthly vesting schedule starting on that date. Following the RSU grant, his directly held common stock position is 194,855 shares.

Absci Corp Chief Legal Officer Shelby J. Walker reported equity awards and a related tax-withholding share disposition. On March 2, Walker received a grant of 90,300 shares of common stock as restricted stock units under Absci’s 2021 Stock Option and Incentive Plan, and a separate stock option covering 356,300 shares at an exercise price of $0.00 per share.

The RSUs and the option are scheduled to vest in three substantially equal annual installments beginning on March 1, 2027, subject to continued service. On March 3, 9,825 shares of common stock at $2.80 per share were withheld by Absci to cover tax obligations tied to RSU vesting, which the filing states was not a discretionary trade. After these transactions, Walker directly owned 139,775 shares of common stock.

Absci Corp Chief Executive Officer Sean McClain reported equity compensation and related tax withholding transactions. On March 2, 2026, he received 406,200 shares of common stock as a restricted stock unit award and a stock option for 1,603,200 shares at an exercise price of $0.00 per share, both vesting in three equal annual installments starting March 1, 2027, subject to continued service. On March 3, 2026, 25,316 shares of common stock were withheld at $2.80 per share to cover tax obligations from RSU vesting, which the filing states was not a discretionary trade.

Absci Corp executive Todd Bedrick reported equity compensation changes. He received 49,600 shares of common stock as restricted stock units and a stock option for 195,900 shares, while 5,282 shares were withheld at about $2.80 per share to cover tax on vesting rather than from a discretionary sale.

Absci Corp CFO/CBO Zachariah Jonasson reported multiple equity compensation transactions. He received a grant of 135,400 shares of common stock in the form of restricted stock units under the 2021 Stock Option and Incentive Plan and a stock option covering 534,400 shares.

The RSUs and the option vest in three substantially equal annual installments starting on March 1, 2027, conditional on his continued service. A separate disposition of 10,848 common shares at $2.80 per share reflects shares withheld by Absci to cover tax obligations on RSU vesting and is not a discretionary trade. Following these events, he directly holds 499,783 common shares.